virus
famili
filovirida
repres
signific
health
risk
emerg
infecti
diseas
well
potenti
engin
biothreat
mani
research
effort
publish
offer
possibl
toward
mitig
filovir
infect
remain
sanction
therapeut
vaccin
strategi
current
progress
develop
filoviru
therapeut
vaccin
outlin
herein
respect
current
level
test
evalu
proxim
toward
human
implement
specif
regard
human
clinic
trial
nonhuman
primat
studi
small
anim
studi
vitro
develop
contemporari
method
support
care
previou
treatment
approach
human
patient
also
discuss
famili
filovirida
includ
two
accept
genera
ebolaviru
marburgviru
genu
ebolaviru
includ
five
speci
repres
singl
viru
zair
ebolaviru
ebola
viru
ebov
sudan
ebolaviru
sudan
viru
sudv
reston
ebolaviru
reston
viru
restv
forest
ebolaviru
tai
forest
viru
tafv
bundibugyo
ebolaviru
bundibugyo
viru
bdbv
genu
marburgviru
includ
singl
speci
marburg
marburgviru
two
member
marburg
viru
marv
ravn
viru
ravv
first
case
filovir
infect
document
three
simultan
outbreak
west
germani
yugoslavia
viru
respons
outbreak
name
marburg
viru
german
citi
marburg
first
recogn
document
instanc
infect
seem
member
filoviru
genera
may
exist
quit
opposit
climat
africa
marburgviru
infect
occur
frequent
dri
woodland
ebolaviru
infect
occur
frequent
rain
forest
year
effort
focus
search
reservoir
virus
africa
search
still
ongo
recent
evid
indic
bat
may
reservoir
marburgvirus
ebolavirus
howev
recent
outbreak
restv
domest
pig
philippin
demonstr
potenti
anim
primat
bat
infect
potenti
spread
amplifi
outbreak
filovirus
name
long
filament
shape
seen
order
micromet
length
width
narrow
usual
around
nm
littl
fluctuat
contain
within
filament
viru
singl
negativesens
rna
genom
encod
seven
protein
seven
filovir
protein
glycoprotein
gp
polymeras
l
nucleoprotein
np
secondari
matrix
protein
transcript
activ
polymeras
cofactor
matrix
protein
homotrim
viral
gp
cover
surfac
virion
viral
gp
believ
sole
host
attach
factor
filovirus
candid
filovir
receptor
cofactor
includ
transferrin
dcsign
entri
filovirus
replic
genom
viral
protein
cytoplasm
use
rnadepend
rnapolymeras
carri
viru
wildtyp
filoviru
infect
associ
sever
case
fatal
rate
human
high
human
filoviru
infect
character
abrupt
onset
flulik
ill
initi
incub
period
day
follow
initi
ill
sign
symptom
diseas
includ
anorexia
nausea
vomit
chest
pain
cough
edema
postur
hypotens
neurolog
complic
petechia
mucos
hemorrhag
also
sever
observ
wildtyp
filoviru
outbreak
among
great
ape
africa
demonstr
similarli
high
mortal
rate
effort
creat
cost
timeeffect
model
filovir
diseas
develop
vaccin
therapeut
small
anim
mice
guinea
pig
often
use
howev
anim
usual
demonstr
signific
resist
wildtyp
filoviru
infect
demonstr
mortal
rate
similar
primat
filoviru
question
adapt
model
speci
due
difficulti
evalu
wildtyp
filoviru
infect
small
anim
gener
high
level
immun
protect
correl
deriv
nonhuman
primat
nhp
model
infect
therapeut
vaccin
ultim
evalu
nhp
speci
efficaci
filoviru
nhp
model
avail
filoviru
studi
rhesu
cynomolgu
macaqu
highli
character
util
therapeut
vaccin
develop
respect
howev
start
point
vaccin
therapeut
develop
remain
small
anim
model
due
cost
ethic
timeassoci
benefit
review
highlight
current
research
filoviru
vaccin
therapeut
current
clinic
standard
filovir
infect
support
care
current
fdaapprov
treatment
strategi
support
care
consist
oral
fluid
rehydr
oral
medic
nutrit
supplement
psychosoci
support
nasogastr
feed
tube
iv
administr
fluid
medic
increasingli
consid
support
care
possibl
outbreak
scenario
prevent
dehydr
facilit
support
blood
pressur
howev
given
limit
equip
laboratori
support
outbreak
care
must
taken
prevent
overaggress
fluid
administr
fluid
replac
evalu
briefli
rhesu
macaqu
signific
benefit
surviv
less
sever
renal
compromis
observ
support
care
may
may
reduc
overal
case
fatal
rate
human
true
impact
simpl
intervent
fluid
manag
yet
fulli
evalu
potenti
benefit
combin
direct
antivir
measur
yet
assess
treatment
filoviru
infect
passiv
transfer
antibodi
attract
therapi
conflict
result
vitro
anim
human
recent
breakthrough
solidifi
potenti
strategi
intervent
addit
number
immunotherapi
develop
agent
respiratori
syncyti
viru
rsv
provid
potenti
roadmap
preced
facilit
advanc
product
necessari
regulatori
hurdl
transfer
immun
serum
treatment
filoviru
infect
human
previous
attempt
howev
interpret
result
cautiou
due
studi
condit
well
uncertainti
diseas
stage
individu
treat
result
much
attent
focus
anim
studi
evalu
candid
product
mani
earli
studi
mice
guinea
pig
success
success
translat
nhp
studi
temper
enthusiasm
evalu
candid
product
similar
passiv
transfer
strategi
attempt
nhp
viremia
onset
outward
sign
diseas
reduc
treatment
affect
survivorship
addit
suggest
antibodi
could
enhanc
filoviru
infect
vitro
caus
concern
howev
recent
seri
experi
made
research
develop
fund
agenc
reconsid
potenti
categori
product
filovirus
polyclon
monoclon
passiv
therapi
shown
efficaci
rodent
filoviru
infect
furthermor
evid
enhanc
antibodi
exist
antibodi
respons
ebov
recent
studi
demonstr
protect
macaqu
polyclon
monoclon
passiv
therapi
sourc
monoclon
antibodi
rang
murin
monoclon
antibodi
recombinantderiv
clone
human
monoclon
antibodi
survivor
filoviru
infect
develop
new
antibodi
use
postexposur
treatment
ongo
one
studi
antibodi
target
ebov
gp
mucinlik
domain
gener
subsequ
shown
protect
mice
lethal
ebov
challeng
given
day
postexposur
antibodi
modifi
gener
human
recombin
antibodi
human
recombin
antibodi
also
significantli
protect
mice
lethal
challeng
ebov
anoth
method
recombin
use
gener
total
monoclon
antibodi
subsequ
character
monoclon
antibodi
improv
surviv
rate
mice
highdos
lethal
challeng
mouseadapt
ebov
anoth
antibodi
isol
bone
marrow
human
survivor
ebov
infect
specif
complex
neutral
ebov
vitro
offer
protect
lethal
ebov
challeng
rodent
model
nonprotect
nhp
tabl
dna
vaccin
first
clinic
trial
involv
filoviru
vaccin
base
plasmid
express
ebov
np
gp
well
sudv
gp
strategi
prove
safe
subject
involv
phase
test
howev
primeboost
dna
vaccin
strategi
cover
four
separ
plasmid
dose
administ
three
time
ineffect
creat
durabl
immun
evidenc
near
nonexist
antibodi
titer
subject
year
clinic
trial
vaccin
halt
may
possibl
strategi
supplement
anoth
vaccin
technolog
primeboost
capac
vaccin
therapeut
current
licens
use
fda
phase
clinic
trial
safeti
test
perform
one
particular
platform
ebov
vaccin
vaccin
base
replic
defici
recombin
adenoviru
serotyp
vector
genet
engin
carri
gene
ebov
glycoprotein
gp
z
sudv
glycoprotein
gp
sg
common
human
pathogen
vector
vaccin
util
broadtrop
adenoviru
vector
infect
cell
insid
insert
ebolaviru
glycoprotein
express
upon
express
insert
ebolaviru
gene
host
immun
system
recogn
foreign
mount
respons
advanc
vaccin
technolog
phase
trial
manifest
abil
provid
protect
among
cynomolgu
macaqu
vaccin
day
prior
challeng
abil
gener
potent
humor
cellmedi
immun
respons
clinic
trial
particip
remain
asymptomat
singl
vaccin
either
viral
particl
furthermor
dose
vaccin
signific
antibodi
titer
observ
week
postvaccin
particip
receiv
viral
particl
posit
gp
sg
gp
z
respect
signific
antibodi
titer
observ
week
postvaccin
decreas
week
demonstr
potenti
durabl
vaccin
time
tcell
activ
also
examin
individu
found
directli
correl
dose
administ
lesser
extent
previous
mention
antibodi
respons
activ
observ
greater
frequenc
activ
receiv
vaccin
importantli
result
obtain
context
signific
preexist
immun
preentri
evalu
antibodi
titer
reveal
particip
posit
show
preexist
immun
still
result
protect
ebov
studi
show
great
promis
develop
addit
studi
nhp
human
need
tabl
addit
adenoviru
platform
clinic
trial
addit
variat
vaccin
also
develop
evalu
nhp
model
base
adenoviru
vector
platform
complex
adenoviru
cadvax
technolog
substanti
increas
genet
payload
capac
vector
kb
addit
strategi
involv
blend
four
separ
vector
express
glycoprotein
ebov
sudv
marv
along
nucleoprotein
ebov
marv
administ
primeboost
strategi
technolog
offer
protect
ebov
sudv
marv
anoth
variat
cadvax
system
design
express
modifi
ebov
glycoprotein
sudv
glycoprotein
effect
protect
parenter
aerosol
challeng
administ
primeboost
strategi
implement
cadvax
technolog
demonstr
signific
antibodi
titer
improv
upon
adenovirusbas
ebov
vaccin
technolog
ongo
richardson
et
al
reformat
genet
insert
vector
includ
addit
cytomegaloviru
cmv
chicken
hybrid
promot
optim
codon
consensu
kozak
sequenc
improv
led
threeto
sevenfold
increas
ebov
glycoprotein
express
neutral
antibodi
titer
found
dose
low
infecti
form
unit
ifu
compar
titer
requir
ifu
unmodifi
vaccin
mice
modif
demonstr
protect
mice
dose
two
order
magnitud
lower
unmodifi
vaccin
interestingli
min
postchalleng
modifi
adcmvzgpadcagoptzgp
offer
protect
compar
protect
mice
offer
origin
vaccin
vector
format
also
recent
show
promis
administ
sublingu
mice
therefor
elimin
complex
parenter
administr
necess
steril
tool
asept
chemic
risk
potenti
bloodborn
pathogen
exposur
adenoviru
vector
vaccin
technolog
promis
demonstr
preexist
immun
vector
depress
desir
immun
respons
may
imped
implement
effort
circumv
issu
preexist
immun
geisbert
et
al
sought
less
preval
serovari
studi
heterolog
primeboost
strategi
recombin
adenoviru
serotyp
carri
gp
z
gp
sg
demonstr
complet
protect
among
nhp
vector
capabl
stimul
humor
cellmedi
immun
respons
context
nhp
prevaccin
evidenc
antibodi
titer
reach
order
magnitud
achiev
vaccin
subject
compar
intracellular
cytokin
stain
greater
among
heterolog
primeboost
subject
compar
rhabdovirus
recent
offer
uniqu
vaccin
platform
gener
genusspeci
specif
immun
well
potenti
crossprotect
immun
filovirus
exampl
base
attenu
recombin
vesicular
stomat
viru
rvsv
replicationcompet
viru
express
glycoprotein
target
filoviru
place
wildtyp
membran
glycoprotein
viru
primarili
agricultur
pathogen
preexist
immun
interf
desir
immun
respons
subsequ
protect
unlik
sever
studi
begun
address
safeti
filoviru
vsv
platform
evalu
platform
immunocompromis
nhp
suggest
technolog
may
safe
among
similarli
immunocompromis
human
encourag
safeti
liveattenu
vaccin
came
recent
mire
et
al
show
ebov
marv
rvsv
show
sign
neurovirul
associ
vsv
util
vsvbase
vaccin
protect
filovir
hemorrhag
fever
highlight
geisbert
et
al
use
blend
vaccin
consist
equal
amount
three
differ
vsv
vector
carri
ebov
sudv
marv
glycoprotein
abl
gener
protect
nhp
challeng
ebov
sudv
tafv
marv
observ
ill
effect
replicationcompet
vaccin
vaccin
nhp
one
show
sign
viremia
assay
rtpcr
vaccin
nhp
also
demonstr
elev
antibodi
respons
vaccin
titer
rang
three
glycoprotein
compon
blend
vaccin
addit
provid
high
level
protect
prophylact
vaccin
strategi
vsvbase
technolog
demonstr
postexposur
protect
ebov
marv
administ
via
intramuscular
im
inject
marvrvsv
administ
im
min
postchalleng
marv
nhp
surviv
studi
viral
rna
observ
blood
day
three
postchalleng
assay
rtpcr
activ
viru
unobserv
tradit
plaqu
assay
clinic
chemistri
result
demonstr
surviv
nhp
experienc
signific
rise
aspart
aminotransferas
gammaglutamyl
transferas
total
bilirubin
blood
urea
nitrogen
indic
protect
postexposur
treatment
complet
prevent
typic
pathogen
event
associ
marv
infect
similar
experi
demonstr
sudvrvsv
deliv
min
challeng
offer
protect
postexposur
protect
ebovrvsv
less
effect
min
still
afford
protect
eight
nhp
postexposur
treatment
ebov
glycoprotein
rvsv
use
recent
h
suspect
human
exposur
via
needlestick
laboratori
direct
evid
laboratori
worker
inde
expos
person
surviv
experi
discern
sequela
treatment
outsid
transient
fever
occur
h
inject
plaqu
form
unit
pfu
also
note
rhabdovirusbas
filovir
vaccin
recent
report
gener
dual
immun
ebov
rabi
viru
infect
ebov
gp
effici
express
attenu
vaccin
use
wildlif
rabi
viru
place
wildtyp
rabi
envelop
glycoprotein
g
vaccin
vector
capabl
induc
protect
immun
ebov
infect
well
rabi
viru
infect
liveattenu
format
inactiv
vaccin
neurovirul
recombin
vector
unobserv
suckl
mice
compar
unalt
vaccin
versatil
offer
increas
storag
option
inactiv
vaccin
well
opportun
vaccin
diseas
endem
alphaviru
particlebas
vaccin
also
provid
high
level
protect
nhp
lethal
filoviru
challeng
vaccin
ebov
sudv
marv
compos
venezuelan
equin
enceph
viru
veev
base
replicon
particl
vrp
express
viral
glycoprotein
interest
replicon
particl
replicationdefect
singlecycl
vector
spread
celltocel
vrp
compos
attenu
veev
replicon
contain
veev
nonstructur
gene
filoviru
glycoprotein
vrp
gener
replicon
cotransfect
cell
helper
plasmid
contain
veev
structur
gene
result
singlecycl
propag
defect
particl
administ
appropri
anim
model
efficaci
test
technolog
offer
sever
advantag
includ
high
express
level
heterolog
gene
dendrit
cell
tropism
induct
robust
cellular
antibodi
immun
respons
rapid
construct
singl
multival
vaccin
rel
resist
antivector
immun
vivo
studi
marv
vrp
offer
first
demonstr
fulli
protect
filoviru
vaccin
nhp
exhibit
surviv
vaccin
focu
form
unit
ffu
vrp
three
consecut
dose
space
day
interv
prior
challeng
marv
protect
offer
vrp
construct
express
gp
alon
gp
np
howev
nhp
vaccin
np
alon
exhibit
clinic
symptom
ill
two
three
surviv
challeng
substanti
antibodi
titer
found
vaccin
nhp
addit
conspicu
elev
clinic
chemistri
observ
nhp
throughout
experi
experi
perform
mice
guinea
pig
support
abil
vrp
express
gp
mediat
complet
protect
lethal
marv
ebov
challeng
mice
adopt
transfer
cell
cell
passiv
antibodi
transfer
vrpnpimmun
mice
protect
suggest
vaccin
may
protect
stimul
host
cellmedi
immun
respons
addit
adopt
transfer
tcell
activ
via
specif
ebov
peptid
provid
mice
complet
protect
indic
mechan
vrpbase
immun
recent
studi
indic
vrpbase
vaccin
fulli
protect
cynomolgu
macaqu
ebov
sudv
marv
parenter
aerosol
viru
challeng
unpublish
observ
oling
paramyxovirusbas
vector
vaccin
filovir
threat
recent
demonstr
capac
protect
nhp
infect
stimul
strong
immun
respons
paramyxovirus
natur
tropism
respiratori
tract
filovirus
emerg
diseas
potenti
weapon
threat
idea
target
vaccin
area
ideal
two
candid
categori
vaccin
investig
date
human
parainfluenza
viru
newcastl
diseas
viru
ndv
two
system
system
evalu
nhp
model
ebov
infect
combin
ebov
gp
alon
ebov
gp
np
ebov
gp
human
granulocyt
macrophag
coloni
stimul
factor
gmcsf
insert
genom
vaccin
vector
use
vaccin
nhp
intranas
intratrach
initi
studi
offer
complet
protect
guinea
pig
vaccin
via
respiratori
rout
least
one
nhp
three
vaccin
group
receiv
tcid
median
tissu
cultur
infect
dose
respect
vector
display
clinic
sign
ill
challeng
studi
group
held
two
nhp
three
group
one
vaccin
anim
ebov
gp
np
succumb
diseas
immun
respons
subject
prior
challeng
reveal
antibodi
titer
rang
manipul
dose
administr
strategi
bukreyev
et
al
abl
achiev
complet
protect
nhp
two
success
dose
tcid
given
day
zero
day
challeng
occur
day
twodos
strategi
produc
igg
titer
rang
much
higher
singl
dose
experi
highlight
potenti
platform
ebov
vaccin
known
preval
preexist
immun
human
could
hinder
gener
target
immun
address
concern
bukreyev
et
al
compar
immunogen
ebov
gp
express
vector
among
preimmun
nhp
experi
ebovspecif
igg
level
substanti
decreas
among
preimmun
nhp
howev
hindranc
overcom
nhp
vaccin
two
dose
recombin
vector
previous
shown
offer
complet
protect
ebov
challeng
effort
diversifi
paramyxovirusbas
vector
avoid
issu
surround
preexist
immun
found
new
vector
design
base
ndv
establish
ndv
avian
paramyxoviru
infect
respiratori
tract
viru
shown
highli
attenu
nhp
due
natur
host
restrict
process
addit
vector
system
proven
success
vaccin
platform
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
influenza
nhp
although
system
yet
evalu
context
nhp
model
ebov
infect
diseas
recent
shown
immunogen
nhp
singl
vaccin
ndv
express
ebov
gp
produc
lower
titer
platform
demonstr
vector
less
immunogen
howev
homolog
primeboost
vaccin
strategi
ebovspecif
mucos
iga
level
reach
similar
homolog
prime
boost
vaccin
strategi
igg
specif
ebov
reach
level
compar
previou
platform
report
support
potenti
use
paramyxovirus
vaccin
candid
examin
immunostimulatori
effect
preexist
immun
requir
investig
vlp
technolog
work
gener
nonrepl
viru
particl
contain
filovir
genet
materi
immun
respons
gener
respons
exposur
vlp
deriv
filovir
protein
shell
vlp
vlp
construct
matrix
protein
abil
drive
bud
process
simpl
transfect
express
target
cell
filament
structur
gener
coexpress
addit
filovir
protein
gp
np
dramat
enhanc
stabil
product
vlp
target
cell
tradit
targetproduct
cell
swap
insect
cell
filovir
protein
express
driven
baculoviru
vector
vlp
gener
found
filament
structur
resembl
wildtyp
viru
vlp
demonstr
immunogen
abil
protect
nhp
lethal
challeng
first
studi
involv
nhp
util
baculovirusproduc
vlp
contain
ebov
gp
np
five
cynomolgu
macaqu
vaccin
three
time
interv
vlp
ribi
adjuv
full
vaccin
schedul
surviv
lethal
ebov
challeng
threeto
tenfold
increas
ebov
specif
antibodi
possess
plaqu
reduct
titer
addit
antibodi
shown
complimentmedi
antibodydepend
cellmedi
cytotox
properti
use
vlp
technolog
swenson
et
al
abl
show
similar
effect
marv
three
im
inject
mg
vlp
ml
adjuv
space
day
apart
offer
protect
marv
ravv
howev
one
anim
challeng
ravv
exhibit
slight
morbid
anim
detect
viremia
determin
plaqu
assay
day
postexposur
addit
two
inject
vlp
correl
peak
homolog
antibodi
titer
three
inject
correl
peak
heterolog
antibodi
titer
abil
vlp
gener
protect
immun
filovir
challeng
demonstr
guinea
pig
well
tabl
immunogen
viruslik
particl
vlp
ebov
marv
easili
gener
mammalian
system
ebovlik
particl
vlp
effici
gener
mammalian
cell
express
alon
filoviru
protein
coexpress
well
baculovirusderiv
vlp
also
success
gener
insect
cell
stimul
cellular
antibodi
immun
respons
hepat
e
viru
human
papilloma
viru
rotaviru
simian
immunodefici
viru
sever
group
made
test
baculovirusgener
filovirusvlp
vaccin
small
anim
model
warfield
et
al
gener
ebolavlp
evlp
marburgvlp
mvlp
contain
np
gp
vaccin
surviv
follow
lethal
infect
mice
vaccin
dosedepend
sun
et
al
produc
evlp
contain
gp
vaccin
also
effect
follow
lethal
ebov
infect
mice
vaccin
dosedepend
mani
report
document
abil
filovir
gp
act
potent
immunogen
viral
vector
popular
method
vaccin
express
gp
host
subsequ
immun
recognit
howev
recent
report
sought
util
gp
vaccin
agent
order
effici
produc
protein
express
vector
construct
fc
portion
human
igg
fuse
ebovgp
gpfc
fusion
protein
induc
cellmedi
humor
immun
respons
mice
vaccin
zebovgpfc
demonstr
protect
lethal
ebov
challeng
studi
requir
result
show
vaccin
ebovgpfc
alon
effect
lethal
ebov
infect
thu
fusion
protein
could
potenti
use
effect
vaccin
filovirus
use
plant
produc
vaccin
antigen
antibodi
demonstr
previous
attract
sever
reason
includ
low
manufactur
cost
effici
product
minim
risk
contamin
human
pathogen
toxin
fact
plant
similar
secretori
pathway
endosom
system
mammalian
cell
recent
bean
yellow
dwarf
viru
beydv
deriv
replicon
system
develop
shown
effici
produc
antibodi
ebov
nicotiana
benthamiana
leav
poolcharoen
et
al
use
system
develop
fuse
cterminu
igg
heavi
chain
ebov
immun
complex
eic
use
vaccin
immun
mice
serum
antibodi
respons
test
show
eic
highli
immunogen
mice
produc
antibodi
level
similar
mice
protect
lethal
ebov
challeng
antibodi
titer
alon
fulli
correl
protect
lethal
challeng
potenti
develop
vaccin
replic
vaccin
could
spread
target
popul
initi
inocul
would
attract
altern
approach
filoviru
develop
approach
could
provid
high
coverag
minim
initi
vaccin
cmvbase
vaccin
would
allow
type
spread
cmv
member
famili
betaherpesvirina
induc
high
effector
memori
tcell
em
respons
establish
lowlevel
persist
infect
high
immunogen
make
cmv
good
potenti
vaccin
vector
cmv
vector
previous
shown
effect
vaccin
siv
rhesu
macaqu
tsuda
et
al
construct
mous
cmv
vector
express
cell
epitop
nucleoprotein
np
ebov
mcmvebovnpctl
vaccin
induc
high
level
ebovspecif
cell
subsequ
protect
mice
lethal
ebov
challeng
show
proofofconcept
cmv
potenti
vaccin
vector
ebov
discuss
previous
paramyxovirusbas
vector
demonstr
capac
induc
strong
immun
respons
protect
anim
infect
chimer
develop
surfac
markersreceptor
delet
replac
ebovgp
chimer
viru
amplifi
recov
easili
addit
chimer
viru
greater
incorpor
ebovgp
virion
due
lack
competit
surfac
protein
test
guinea
pig
show
highli
attenu
compar
immunogen
develop
neutral
antibodi
ebov
final
pfu
inocul
abl
protect
guinea
pig
lethal
ebov
challeng
tabl
sever
coagul
disord
one
promin
featur
filovir
infect
event
breach
vascular
integr
strict
balanc
proand
anticoagul
host
factor
must
maintain
success
clot
breach
prevent
much
littl
clot
format
instanc
filoviru
infect
sustain
microvascular
injuri
effect
organ
result
host
coagul
inhibitor
deplet
result
dissemin
intravascular
coagul
dic
dic
tissu
factor
tf
clot
factor
normal
present
cell
expos
blood
complex
circul
factor
vii
lead
clot
format
fibrin
deposit
extrins
pathway
numer
studi
demonstr
clear
link
dic
result
organ
failur
geisbert
et
al
sought
elimin
potenti
tf
pathogenesi
filoviru
infect
use
recombin
nematod
anticoagul
protein
demonstr
inhibitor
tf
pathway
provid
partial
postexposur
protect
rhesu
macaqu
filoviru
infect
previou
studi
alreadi
gone
phase
ii
trial
orthoped
surgeri
coronari
revascular
geisbert
et
al
show
surviv
rate
addit
increas
mean
timetodeath
ebovinfect
rhesu
macaqu
surviv
rate
increas
mean
timetodeath
marvinfect
rhesu
macaqu
treat
postexposur
normal
lethal
model
filoviru
infect
demonstr
clear
benefit
surviv
increas
mean
timetodeath
observ
complet
phase
ii
clinic
trial
good
safeti
record
primat
comparison
current
drug
candid
highest
level
develop
either
human
clinic
trial
shown
promis
nhp
also
list
afford
level
protect
nhp
type
drug
use
induc
immun
dose
paradigm
use
achiev
list
result
phosphorodiamid
morpholino
oligom
pmo
exert
antitransl
effect
steric
hindranc
translat
machineri
steric
hindranc
possibl
due
morpholino
group
similar
ribos
base
rna
methylen
phosphorodiamid
link
moieti
physic
bind
mrna
prevent
translat
machineri
access
mrna
antisens
pmo
bind
target
mrna
highli
stabl
highli
solubl
would
allow
high
level
translat
inhibit
predict
low
level
potenti
cytotox
pmo
previous
demonstr
effect
antivir
activ
coronavirus
flavivirus
swenson
et
al
initi
util
pmo
target
ebov
ebov
highli
protect
mice
guinea
pig
lethal
challeng
ebov
marv
subsequ
combin
pmo
ebov
combin
pmo
marv
np
develop
test
nhp
postexposur
scenario
pmo
deliv
min
postexposur
protect
rhesu
macaqu
lethal
ebov
infect
cynomolgu
macaqu
marv
infect
eas
control
manufactur
efficaci
nhp
model
combat
filoviru
infect
pmo
repres
viabl
therapeut
strategi
current
phase
clinic
trial
tabl
recombin
human
activ
protein
c
ebolaviru
diseas
evd
sever
sepsi
septic
shock
share
mani
clinic
featur
includ
fever
hypotens
increas
product
tissu
factor
elev
level
nitric
oxid
elev
level
ddimer
addit
promin
consist
find
sever
sepsi
sever
protein
c
defici
shown
treatment
patient
sever
sepsi
recombin
human
activ
protein
c
rhapc
result
improv
surviv
later
experi
nhp
demonstr
ebov
infect
result
rapid
reduct
circul
protein
c
level
therefor
test
treatment
rhapc
could
protect
lethal
ebov
infect
rhesu
macaqu
fourteen
rhesu
macaqu
infect
lethal
dose
ebov
eleven
treat
iv
rhapc
min
challeng
continu
day
control
anim
die
day
postexposur
howev
rhapctreat
anim
surviv
surviv
addit
mean
timetodeath
rhapctreat
anim
day
signific
compar
day
observ
placebo
histor
control
product
pull
singl
postexposur
treatment
given
intervent
directli
target
viru
may
addit
merit
assess
product
conjunct
direct
antivir
rna
interfer
rnai
repres
power
natur
occur
biolog
strategi
inhibit
gene
express
rnai
interfer
translat
mrna
protein
product
either
steric
block
mrna
trigger
rnase
hmediat
cleavag
dnarna
duplex
result
inhibit
gene
express
mani
year
rnai
demonstr
clear
efficaci
prevent
viral
replic
vitro
number
virus
includ
coxsackievirus
hepat
b
viru
hbv
hepat
c
viru
hcv
herpesvirus
human
immunodefici
viru
hiv
human
papillomaviru
rsv
influenza
viru
lymphocyt
choriomening
viru
poliovirus
sarscov
fowler
et
al
demonstr
smallinterf
rna
sirna
downregul
variou
marv
mrna
transcript
abl
significantli
decreas
viral
protein
product
subsequ
viral
releas
cell
cultur
unfortun
effici
deliveri
vehicl
provid
effect
drug
target
stabil
hinder
applic
rnai
clinic
set
howev
recent
develop
field
nanotechnolog
made
nanoparticl
solut
increas
pharmacokinet
profil
rnai
therapi
addit
tekmira
inc
develop
proprietari
lipid
encapsul
mean
improv
pharmacolog
sirna
target
ebola
rna
polymeras
l
protein
demonstr
geisbert
et
al
effici
deliv
sirna
target
cell
mixtur
lipid
form
bilay
liposom
stabl
nucleic
acidlipid
particl
snalp
design
snalp
ensur
cell
entri
preferenti
fuse
endosom
membran
upon
exposur
decreas
ph
endosom
snalp
modifi
conjug
polyethylen
glycol
peg
ensur
stabil
effici
deliveri
sirna
payload
neutral
surfac
charg
present
hydrophil
exterior
encapsul
initi
demonstr
significantli
increas
stabil
halflif
effect
sirna
direct
hbv
snalpencapsul
sirna
target
ebov
l
protein
initi
shown
complet
protect
guinea
pig
administ
shortli
lethal
ebov
challeng
treatment
assess
efficaci
rhesu
macaqu
snalpencapsul
sirna
target
ebov
l
polymeras
given
rhesu
monkey
either
four
seven
time
follow
lethal
challeng
ebov
two
three
monkey
given
four
dose
surviv
lethal
infect
four
monkey
given
seven
dose
surviv
infect
enhanc
survivorship
among
snalptreat
group
highlight
efficaci
potenti
therapeut
addit
littl
evid
side
effect
associ
treatment
group
asid
mildli
alter
liver
enzym
level
could
artifact
separ
challeng
cours
tabl
innat
immun
often
first
line
defens
invad
pathogen
one
mechan
innat
immun
function
reli
identif
pathogenassoci
molecular
pattern
pamp
pamp
consist
uniqu
carbohydr
moieti
extern
surfac
foreign
microb
hexos
mannos
express
surfac
host
cell
pamp
recogn
host
protein
mannosebind
lectin
mbl
recogn
high
hexos
mannos
content
filovirus
larg
amount
mannos
compris
glycoprotein
thu
target
mbl
upon
exposur
host
mbl
target
filovirus
complimentdepend
viru
neutral
lectin
pathway
compliment
cascad
administ
supraphysiolog
dose
lethal
challeng
ebov
recombin
mbl
treatment
protect
mice
studi
show
mbl
may
potenti
postexposur
prophylact
tabl
postexposur
treatment
effect
small
anim
model
comparison
current
treatment
candid
small
anim
model
level
develop
specif
mous
model
also
list
afford
level
protect
type
drug
use
induc
immun
dose
paradigm
use
achiev
list
result
highthroughput
screen
ht
signific
tool
novel
drug
discoveri
ht
involv
screen
librari
consist
thousand
hundr
thousand
uniqu
molecul
specif
target
avail
librari
use
ht
includ
natur
compound
peptid
drug
synthet
compound
recent
compound
identifi
screen
ebovgfp
pseudotyp
viru
shown
strong
antivir
activ
vitro
high
dose
ebov
marv
subsequ
shown
protect
mice
lethal
challeng
ebov
marv
addit
compound
initi
identifi
similar
manner
shown
exhibit
strong
antivir
activ
vitro
ebov
rift
valley
fever
viru
rvfv
four
type
dengu
viru
denv
hcv
also
protect
mice
lethal
challeng
ebov
given
postexposur
taken
togeth
suggest
probabl
act
conserv
pathway
common
four
virus
potenti
make
intrigu
antivir
second
screen
done
use
collect
small
molecul
compound
obtain
nci
ebovgfp
pseudotyp
viru
result
nsc
reactiv
oxygen
speci
scaveng
identifi
shown
high
antivir
activ
ebov
marv
lassa
viru
rvfv
veev
vivo
studi
demonstr
compound
protect
mice
lethal
challeng
ebov
marv
given
either
preor
postexposur
metal
ionbas
therapeut
new
potenti
class
drug
differ
carbonbas
compound
due
charg
central
ion
determin
molecular
geometri
compound
uniqu
molecular
geometri
specif
compound
isol
inhibit
biolog
process
unlik
tradit
carbonbas
compound
uniqu
geometri
differ
allow
compound
form
octahedr
squar
planar
molecular
geometri
hexamminecobalt
iii
chlorid
cohex
complex
cobalt
iii
ion
surround
six
ammonia
ligand
full
octahedr
coordin
cohex
initi
report
antivir
activ
adenoviru
sindbi
viru
subsequ
thought
potenti
broadspectrum
antivir
activ
cohex
shown
welltoler
mice
appar
toxic
mice
treat
cohex
daili
infect
lethal
dose
ebov
cohextr
mice
signific
increas
mean
timetodeath
highest
concentr
treatment
group
surviv
rate
suggest
cohex
potenti
effect
treatment
ebov
infect
niemannpick
cholesterol
transport
found
endosom
lysosom
recent
identifi
requir
ebov
replic
gene
trap
screen
cell
use
replicationcompet
vsv
bear
ebov
glycoprotein
rvsvgpebov
experi
cell
nonfunct
demonstr
decreas
infect
rvsvgpebov
howev
express
function
rescu
normal
infect
virus
known
affect
calcium
homeostasi
well
endosom
lysosom
fission
fusion
also
shown
involv
releas
loss
caus
neurolog
disord
call
niemannpick
diseas
character
cholesterol
accumul
lysosom
heterozyg
knockout
mice
show
evid
niemannpick
diseas
knockout
mice
protect
lethal
challeng
mous
adapt
ebov
surviv
marv
surviv
addit
small
molecul
identifi
interfer
caus
cellular
phenotyp
similar
defici
subsequ
shown
block
infect
ebov
vitro
heatshock
protein
molecular
chaperon
aid
fold
traffick
proteolyt
process
mani
protein
result
mani
function
inhibitor
design
combat
diseas
cancer
current
sever
drug
phase
ii
clinic
trial
addit
shown
import
replic
negativestrand
virus
well
hcv
hbv
polio
effect
sever
natur
synthet
inhibitor
ebov
replic
test
vitro
result
studi
demonstr
three
inhibitor
significantli
inhibit
replic
ebov
vero
cell
primari
human
monocyt
suggest
use
potenti
therapeut
ebolavirus
express
two
secret
glycoprotein
solubl
gp
sgp
small
solubl
gp
ssgp
sgp
associ
stabil
endotheli
barrier
function
reduct
endotheli
barrier
permeabl
oppos
effect
effect
direct
opposit
observ
role
gp
associ
endotheli
cell
destruct
ssgp
yet
clear
role
infect
gp
form
contain
ident
ntermini
differ
structur
ctermini
differenti
process
ctermini
homodim
sgp
cleav
furin
yield
matur
sgp
retain
cell
longer
compar
sgp
ebov
sudv
tafv
fuse
fc
tag
transfect
cell
infect
capabl
inhibit
ebov
marv
infect
dose
depend
fashion
observ
indic
might
play
import
role
filoviru
pathogenesi
could
exploit
novel
antifilovir
therapeut
mani
event
filoviru
entri
remain
undiscov
fusion
mechan
similar
hiv
sarscov
thought
occur
conform
rearrang
glycoprotein
viral
surfac
result
viral
fusion
cellular
membran
inhibitor
viral
fusion
develop
sarscov
inhibitor
prevent
ctermin
heptad
repeat
envelop
protein
interact
cellular
membran
protein
directli
compet
block
interact
ntermin
heptad
repeat
normal
would
result
format
sixhelix
bundl
requir
membran
fusion
cpeptid
inhibitor
viral
envelop
fusion
limit
success
filovirus
past
like
due
suggest
evid
filoviru
fusion
occur
far
along
endosom
matur
process
howev
cpeptid
conjug
argeninerich
segment
tat
protein
protein
known
endosom
local
conjug
cpeptid
exhibit
mark
antivir
effect
inhibit
ebov
marv
vitro
unfortun
concentr
use
gener
inhibit
vitro
possibl
clinic
set
report
indic
futur
cpeptid
research
may
result
filoviru
entri
prevent
futur
therapeut
recent
report
screen
molecul
demonstr
chlorophyllid
abl
decreas
section
hbv
dna
hbv
antivir
assay
result
obtain
compound
concentr
exhibit
cytotox
effect
molecul
alkyl
porphyrin
contain
copper
compound
carri
charg
neutral
ph
screen
chlorin
compound
metalfre
chlorophyllidelik
molecul
found
potent
subsequ
test
virus
includ
marv
test
chlorin
compound
show
signific
antivir
activ
vitro
marv
compound
also
inhibit
junin
viru
denv
hcv
anoth
recent
studi
examin
librari
compound
yield
candid
capabl
gener
inhibit
pseudotyp
viru
interf
control
viru
candid
compound
benzodiazepin
deriv
show
abil
inhibit
ebov
marv
similar
degre
vitro
result
experi
suggest
compound
act
earli
stage
viral
entri
prevent
infect
unknown
mechan
aryl
methyldien
rhodanin
deriv
identifi
highthroughput
screen
inhibitor
nipah
viru
entri
context
vsvpseudotyp
vector
compound
subsequ
shown
inhibit
varieti
envelop
virus
includ
marv
ebov
nipah
rvfv
hcv
wnv
etc
howev
inhibit
nonenvelop
virus
adenoviru
reoviru
test
demonstr
bind
viral
membran
prevent
viruscel
fusion
initi
test
mice
show
antivir
efficaci
develop
compound
improv
pharmacokinet
potenc
distinctli
possibl
develop
medic
countermeasur
ebov
marv
remain
high
prioriti
substanti
progress
made
past
decad
move
inabl
protect
infect
variou
anim
model
diseas
realm
medic
countermeasur
protect
prophylact
recent
success
treatment
employ
follow
known
exposur
virus
initi
effort
focus
prevent
diseas
vaccin
strategi
rang
subunit
vaccin
vlp
vector
system
dna
vaccin
liveattenu
viru
system
express
ebov
marv
glycoprotein
aim
vaccin
efficaci
achiev
multipl
vaccin
parenter
aerosol
rout
exposur
success
new
vaccin
platform
attent
past
year
focus
abil
treat
infect
patient
anim
model
success
demonstr
tradit
small
molecul
antibodi
direct
viru
critic
host
protein
pathway
associ
pathogenesi
abil
util
variou
rna
silenc
technolog
focu
therapeut
could
benefici
filoviru
infect
infecti
diseas
cancer
therapi
despit
success
much
work
adequ
prepar
infecti
threat
abil
provid
benefici
therapeut
impact
point
patient
experi
clinic
symptom
seek
relief
caregiv
remain
hurdl
medic
countermeasur
develop
moreov
qualiti
life
patient
follow
infect
treatment
may
requir
addit
develop
effort
combin
multipl
therapeut
approach
seen
outbreak
clinic
sequela
observ
patient
surviv
infect
sever
life
chang
observ
emphas
need
medic
countermeasur
provid
surviv
also
decreas
morbid
longterm
patholog
outcom
follow
infect
lastli
fund
resourc
fortitud
abil
navig
regulatori
pathway
essenti
reach
either
emerg
use
author
eua
statu
licens
drug
statu
therapeut
vaccin
howev
field
remain
optimist
medic
countermeasur
solut
human
use
possibl
